SIGA Technologies Inc (SIGA)
NASDAQ:SIGA
Want to see SIGA full AI Analyst Report?
Earnings Data
Report Date
Jul 30, 2026After Close (Confirmed)
Period Ending
2026 (Q2)Consensus EPS Forecast
―Last Year’s EPS
0.49Same Quarter Last Year
Based on 0 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call presents a generally positive strategic and financial position driven by a strong cash balance, shareholder-friendly capital return, confirmed near-term international orders, regional commercial expansion via an exclusive Hikma agreement, and concrete pipeline progress (pediatric IND and PEP pathway). Offsetting these positives are the quarter's minimal deliveries and lumpy revenue profile, a small quarterly loss, a CHMP recommendation to withdraw the MPOXX indication in Europe, and slower progress toward a new U.S. government contract. Overall, the positives (liquidity, contracts, partnerships, and pipeline momentum) outweigh the near-term operational and regulatory headwinds.Company Guidance
Strong liquidity and balance sheet
Cash balance of approximately $146 million as of 03/31/2026 with no debt; pro forma cash would remain over $100 million after the special dividend, supporting runway and optional capital deployment.
Shareholder return via special dividend
Declared and paid a special cash dividend of $0.60 per share (record April 7, paid April 23); this marks the fifth consecutive annual special dividend, reflecting confidence in the balance sheet.
Near-term revenue visibility — Q2 expected deliveries
Company expects to deliver approximately $13 million of oral TPOXX to an international customer in Q2 2026, plus additional IV TPOXX deliveries to the Strategic National Stockpile (SNS).
International expansion and commercial partnerships
Received a $13 million order from an Asia-Pacific country to be delivered in Q2; entered into an exclusive license and distribution agreement with Hikma MENA FZE to register and commercialize TPOXX across the Middle East and North Africa, with SIGA as exclusive manufacturer and potential additional payments under certain conditions.
Pipeline progress — pediatric and PEP programs
Filed IND and initiated a Phase 1 pediatric study with results expected in the second half of 2026; PEP program advancing with CDC immunogenicity analyses underway and a targeted FDA submission for the PEP indication within the next 12 months.
Continued government engagement and supportive funding
Maintains engagement with U.S. government stakeholders (HHS); cites $27 million in 2025 funding for pediatric formulation development and IV tech transfer and a 2025 IV TPOXX order as signals of continued role in U.S. preparedness. Oral TPOXX pricing and domestic manufacturing aligned with U.S. government priorities.
SIGA Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
SIGA Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 07, 2026 | $4.73 | $4.80 | +1.48% |
Mar 10, 2026 | $5.00 | $4.84 | -3.10% |
Nov 06, 2025 | $7.23 | $5.79 | -19.95% |
Aug 05, 2025 | $5.84 | $6.42 | +10.00% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does SIGA Technologies Inc (SIGA) report earnings?
SIGA Technologies Inc (SIGA) is schdueled to report earning on Jul 30, 2026, After Close (Confirmed).
What is SIGA Technologies Inc (SIGA) earnings time?
SIGA Technologies Inc (SIGA) earnings time is at Jul 30, 2026, After Close (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is SIGA EPS forecast?
Currently, no data Available